Tesfamariam Andemeskel

Tesfamariam Andemeskel practices at UPMC McKeesport in Mckeesport, Pennsylvania, part of University of Pittsburgh Medical Center.

Tesfamariam Andemeskel's NPI, 1891744918, was assigned on May 8, 2006. Tesfamariam Andemeskel holds Pennsylvania license MD056486L.

Tesfamariam Andemeskel's primary practice is UPMC McKeesport, at 1500 Fifth Avenue, Mckeesport, PA 15132 in Allegheny County. The practice phone is (412) 664-2000.

Tesfamariam Andemeskel's primary practice is UPMC McKeesport in Mckeesport, Pennsylvania, part of University of Pittsburgh Medical Center. Tesfamariam Andemeskel is also affiliated with Select Specialty Hospital - McKeesport. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Tesfamariam Andemeskel to 1 more group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tesfamariam Andemeskel practices, 4 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Tesfamariam Andemeskel's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Tesfamariam Andemeskel is licensed in Pennsylvania.

CMS data shows 169 Medicare services from Tesfamariam Andemeskel across 3 procedure codes in 2024, for 167 Medicare patients. Medicare paid $20,258 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 167 Medicare patients who saw Tesfamariam Andemeskel in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high blood pressure, and 64% have high cholesterol. 47% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Tesfamariam Andemeskel's median patient age at 70, with 49% women.

In 2024, Tesfamariam Andemeskel wrote 212 Medicare Part D claims for 154 patients. 97% of them were for generic drugs. CMS names the drug for 106 of them, across 6 drugs with 11 or more claims each, at $358 in total drug cost. In 2023, CMS named 115 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Tesfamariam Andemeskel for performance year 2024, reported as part of a group. Tesfamariam Andemeskel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.